Adherence and persistence to second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

被引：0
|
作者：
Trivedi, Digisha
Amin, Shahla
Zhu, Ling
Joo, Sam
Kawabata, Hugh
Darkow, Theodore
Hebden, Tony
机构：
[1] Bristol Myers Squibb, Hlth Serv, Plainsboro, NJ USA
[2] Bristol Myers Squibb Co, Global Hlth Econ & Outcomes Res, Pennington, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17009
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
    Jabbour, Elias
    Kantarjian, Hagop
    O'Brien, Susan
    Shan, Jenny
    Garcia-Manero, Guillermo
    Wierda, William
    Ravandi, Farhad
    Borthakur, Gautam
    Rios, Mary Beth
    Cortes, Jorge
    BLOOD, 2011, 117 (06) : 1822 - 1827
  • [42] Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
    Jabbour, Elias
    Kantarjian, Hagop M.
    O'Brien, Susan
    Shan, Jianqin
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Rios, Mary Beth
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4260 - 4265
  • [43] VALIDATION OF A PROGNOSTIC SCORING SYSTEM IN PATIENTS TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER IMATINIB FAILURE
    Boquimpani, C.
    Schaffel, R.
    Graca, D.
    Mesquita, C.
    Peixoto, D.
    Madeira, T.
    Wendling, P.
    Eller, F.
    Biasoli, I.
    Spector, N.
    HAEMATOLOGICA, 2013, 98 : 553 - 553
  • [44] Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront
    Breccia, Massimo
    Molica, Matteo
    Colafigli, Gioia
    Zacheo, Irene
    Latagliata, Roberto
    Tafuri, Agostino
    Alimena, Giuliana
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2206 - 2207
  • [45] Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient- based survey on 1133 patients
    Breccia, Massimo
    Efficace, Fabio
    Sica, Simona
    Abruzzese, Elisabetta
    Cedrone, Michele
    Turri, Diamante
    Gobbi, Marco
    Carella, Angelo Michele
    Gozzini, Antonella
    Usala, Emilio
    Cavazzini, Francesco
    Danise, Paolo
    Tiribelli, Mario
    Binotto, Gianni
    Pregno, Patrizia
    Bocchia, Monica
    Gaidano, Gianluca
    Crugnola, Monica
    Bonifacio, Massimiliano
    Avanzini, Paolo
    Celesti, Francesca
    Guella, Anna
    Martino, Bruno
    Annunziata, Mario
    Luciano, Luigiana
    Stagno, Fabio
    Vallisa, Daniele
    Pungolino, Esther
    Iurlo, Alessandra
    Rambaldi, Alessandro
    Nardiello, Ida
    Orlandi, Esther
    Gambacorti-Passerini, Carlo
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2015, 39 (10) : 1055 - 1059
  • [46] CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FIRST-LINE SECOND-GENERATION TYROSINE KINASE INHIBITORS
    Lee, S.
    Choi, S.
    Kim, S.
    Bang, J.
    Oh, Y.
    Park, J.
    Jeon, H.
    Jang, E.
    Kim, D.
    HAEMATOLOGICA, 2013, 98 : 51 - 52
  • [47] Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors
    Shacham Abulafia, Adi
    Shemesh, Sivan
    Rosenmann, Lena
    Berger, Tamar
    Leader, Avi
    Sharf, Giora
    Raanani, Pia
    Rozovski, Uri
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 9
  • [48] Mutational analysis of T315I in patients with chronic myeloid leukemia who did not respond to second-generation tyrosine kinase inhibitors
    Al-Jadir, Riyam
    Alalsaidissa, Jaffar
    IRAQI JOURNAL OF HEMATOLOGY, 2020, 9 (02) : 131 - 137
  • [49] Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors
    Marce, Silvia
    Zamora, Lurdes
    Cabezon, Marta
    Xicoy, Blanca
    Boque, Concha
    Fernandez, Cristalina
    Grau, Javier
    Navarro, Jose-Tomas
    Fernandez de Sevilla, Alberto
    Ribera, Josep-Maria
    Feliu, Evarist
    Milla, Fuensanta
    MEDICINA CLINICA, 2013, 141 (03): : 95 - 99
  • [50] Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians
    Kekale, Meri
    Talvensaari, Kimmo
    Koskenvesa, Perttu
    Porkka, Kimmo
    Airaksinen, Marja
    PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 1619 - 1627
12345